ArticleJournal of neurosurgical anesthesiology2017
A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.
Article in Journal of neurosurgical anesthesiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.Journal of neurology · 2021Pooled it
- Molecular insights into DNA damage response plasticity in glioma stem cells.Communications biology · 2026Review
- Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma.Science advances · 2026Article
- Hormonal signaling in glioblastoma: emerging roles in stemness and tumor plasticity.Frontiers in endocrinology · 2026Review
- The role of dexamethasone during treatment phases in glioblastoma: Insights from a retrospective observational study.Brain & spine · 2026Article
- Article
- Adjuvant Analgesics in Acute Pain - Evaluation of Efficacy.Current pain and headache reports · 2024Review
- Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival.Acta neurochirurgica · 2023Article
- Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.BMC neurology · 2023Article
- Postcraniotomy Headache: Etiologies and Treatments.Current pain and headache reports · 2022Review
- Article
- Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.Journal for immunotherapy of cancer · 2022Article
- C/EBPß Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think!Journal of mammary gland biology and neoplasia · 2020Review
- Weighted gene co-expression network analysis identified six hub genes associated with rupture of intracranial aneurysms.PloS one · 2020Article
- Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema.Brain : a journal of neurology · 2019Article
- Article
- The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.Immunologic research · 2019Article
- Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.Current treatment options in neurology · 2019Review
- Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity.Molecular and cellular biochemistry · 2019Article
- Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies.Frontiers in molecular neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundDexamethasone is reported to induce both tumor-suppressive and tumor-promoting effects. The purpose of this study was to identify the genomic impact of dexamethasone in glioblastoma stem cell (GSC) lines and its prognostic value; furthermore, to identify drugs that can counter these side effects of dexamethasone exposure.
methodsWe utilized 3 independent GSC lines with tumorigenic potential for this study. Whole-genome expression profiling and pathway analyses were done with dexamethasone-exposed and control cells. GSCs were also co-exposed to dexamethasone and temozolomide. Risk scores were calculated for most affected genes, and their associations with survival in The Cancer Genome Atlas and Repository of Molecular Brain Neoplasia Data databases. In silico Connectivity Map analysis identified camptothecin as antagonist to dexamethasone-induced negative effects.
resultsPathway analyses predicted an activation of dexamethasone network (z-score: 2.908). Top activated canonical pathways included "role of breast cancer 1 in DNA damage response" (P=1.07E-04). GSCs were protected against temozolomide-induced apoptosis when coincubated with dexamethasone. Altered cellular functions included cell movement, cell survival, and apoptosis with z-scores of 2.815, 5.137, and -3.122, respectively. CCAAT/enhancer binding protein beta (CEBPB) was activated in a dose dependent manner specifically in slow-dividing "stem-like" cells. CEBPB was activated in dexamethasone-treated orthotopic tumors. Patients with high risk scores had significantly shorter survival. Camptothecin was validated as potential partial neutralizer of dexamethasone-induced oncogenic effects.
conclusionsDexamethasone exposure induces a genetic program and CEBPB expression in GSCs that adversely affects key cellular functions and response to therapeutics. High risk scores associated with these genes have negative prognostic value in patients. Our findings further suggest camptothecin as a potential neutralizer of adverse dexamethasone-mediated effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.